Effects of Empagliflozin on Gut Microbiota in Heart Failure with a Preserved Ejection Fraction: The Design of a Pragmatic Randomized, Open-Label Controlled Trial (EMPAGUM)
Xue-Qing Guan,Chuan-He Wang,Peng Cheng,Ling-Yu Fu,Qi-Jun Wu,Gong Cheng,Lin Guan,Zhi-Jun Sun
DOI: https://doi.org/10.2147/dddt.s404479
2023-05-18
Abstract:Xue-Qing Guan, 1 Chuan-He Wang, 1 Peng Cheng, 1 Ling-Yu Fu, 2 Qi-Jun Wu, 3– 5 Gong Cheng, 1 Lin Guan, 1 Zhi-Jun Sun 1 1 Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, 110021, People's Republic of China; 2 Department of Clinical Epidemiology and Evidence-Based Medicine, The First Affiliated Hospital, China Medical University, Shenyang, 110021, People's Republic of China; 3 Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, 110021, People's Republic of China; 4 Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, 110021, People's Republic of China; 5 Clinical Research Center, Shengjing Hospital of China Medical University, Shenyang, 110021, People's Republic of China Correspondence: Zhi-Jun Sun, Department of Cardiology, Shengjing Hospital of China Medical University, No. 39 of Huaxiang Road, Tiexi District, Shenyang, 110021, People's Republic of China, Tel +86 02496615, Email Although empagliflozin has been recommended for individuals with heart failure, its effects on heart failure with preserved ejection fraction (HFpEF) remain uncertain from a physiopathological standpoint. The metabolites produced by gut microbiota have been shown to have a crucial role in the development of heart failure. Sodium-glucose cotransporter-2 inhibitors (SGLT2) have been shown to change the make-up of the gut microbiota in rodent studies. There is mixed evidence from similar studies investigating whether or not SGLT2 can affect the microbiota in the human gut. This trial is a pragmatic, randomized, open-label controlled study with empagliflozin as an intervention. We will enroll 100 patients with HFpEF and randomly assign them to one of two groups to receive either empagliflozin or a placebo. Patients in the Empagliflozin group will be given 10 mg of the drug daily, while those in the Control group will not be given empagliflozin or any other SGLT2. The purpose of the trial is to validate the changes that occur in gut microbiota in patients with HFpEF who take empagliflozin and to investigate the function of gut microbiota and their metabolites in the process. Keywords: derived metabolite, gut microbiota, heart failure, HF, myocardial fibrosis, SGLT2, short-chain fatty acids, SCFAs, sodium-glucose cotransporter-2 inhibitor Heart failure (HF) is a complex clinical disease characterized by symptoms and indications caused by any anatomical or functional impairment of ventricular filling or blood ejection. 1 As one of the major cardiac disorders, HF has a significant morbidity and mortality rate around the world. According to data from a multicenter observational study, the combined endpoint of mortality or HF hospitalization after one year was 36% for acute heart failure (AHF) and 14.5% for chronic heart failure (CHF). 2 There were 1.2 million heart failure hospitalizations in the United States in 2017, involving 924,000 patients. This represents a 26% increase over the last decade, and the figure is expected to rise more in the future. 1 Heart failure can be categorized into several phenotypes based on the left ventricular ejection fraction (LVEF), with HFpEF accounting for more than half of all patients. 3 HFpEF is a complex biological process that includes systemic inflammation, epicardial adipose tissue buildup, cardiac fibrosis, and vascular dysfunction, among other metabolic pathways. 4–6 However, the mechanisms and therapeutic strategies for it require additional experimental data. 7 Intestinal flora is a complex collection of microbial communities that are intimately linked to the human body and participate in a variety of biological processes. 8 Patients with heart failure frequently have decreased cardiac output as well as peripheral circulation congestion. In this circumstance, intestinal ischemia and edema cause a disruption in gut flora, resulting in an overproduction of inflammatory agents and toxic metabolites, which accelerates the HF process. 9–11 However, new evidence suggests that gut metabolites play a role in various HF pathways. Some of them (such as SCFAs) have potential protective effects, whereas others (uremic toxins) have the inverse effect. 12 Empagliflozin, a novel type of hypoglycemic medication, is an SGLT2 that blocks glucose reabsorption by the kidneys. As a result, more glucose is excreted in the urine, decreasing blood glucose levels. However, multiple research have revealed other biological effects of SGLT2. SGLT2 has been shown in animal models to reduce sodium consumption, inhibit NO production, enhance cardiac energy metabolism, and regulate -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal